|
Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia. Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia. conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia. Clinical research trials and Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia. medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia.. Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia. Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia. clinical trial. Subjects often receive the most expert healthcare possible for their Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia. condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia. Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia.
Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia.
For Condition: Pneumonia
Status: Completed
Sponsor(s): Pfizer ,
Synopsis: A trial in which patients over 18 years of age who are hospitalized with community acquired pneumonia and are otherwise eligible for entry into the study are randomly selected to receive one of two treatment regimens. After written informed consent is obtained, patients will receive one of the following two treatment regimens: 1) intravenous administration of azithromycin and ceftriaxone followed by azithromycin tablets, or 2) intravenous administration of levofloxacin followed by levofloxacin tablets. At least four study visits are normally conducted up to approximately one month after starting therapy. The objective of this study is to compare the safety and efficacy of the two treatment regimens.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: - Patient must be 18 years or older. - Patient must be hospitalized and require intravenous therapy for treatment of pneumonia - Patient must have pneumonia as documented by relevant signs and symptoms and a positive chest X-ray. - Patients cannot have certain underlying diseases or conditions as defined in the study protocol.
Total Enrollment: 360
Location and Contact Information:
Pfizer Investigational Site
Regina, Saskatchewan, S4P 127
Canada
Pfizer Investigational Site
Philadelphia, Pennsylvania, 19140
United States
Pfizer Investigational Site
Halifax, Nova Scotia, B3H 3A7
Canada
Pfizer Investigational Site
Sellersville, Pennsylvania, 18960
United States
Pfizer Investigational Site
ROTENBURG, Niedersachen, D-27356
Germany
Pfizer Investigational Site
Royal Oak, Michigan, 48073
United States
Pfizer Investigational Site
Detroit, Michigan, 48202
United States
Pfizer Investigational Site
London, Ontario, N6A 4G5
Canada
Pfizer Investigational Site
Ottawa, Ontario, K1Y 4E9
Canada
Pfizer Investigational Site
Shawnee Mission, Kansas, 66204
United States
Pfizer Investigational Site
Sarasota, Florida, 34239
United States
Pfizer Investigational Site
St. Louis, Missouri, 63110
United States
Pfizer Investigational Site
Barcelona, , 08036
Spain
Pfizer Investigational Site
Long Beach, California, 90822
United States
Pfizer Investigational Site
Berlin, , D-14109
Germany
Pfizer Investigational Site
Louisville, Kentucky, 40202
United States
Pfizer Investigational Site
Ft. Gordon, Georgia, 30905
United States
Pfizer Investigational Site
LUEDENSCHEID, , 58515
Germany
Pfizer Investigational Site
Albuquerque, New Mexico, 87108
United States
Pfizer Investigational Site
Phenix City, Alabama, 36867
United States
Pfizer Investigational Site
Columbus, Georgia, 31904
United States
Pfizer Investigational Site
Winnipeg, Manitoba, R3A 1R9
Canada
Pfizer Investigational Site
Kirkwood, Missouri, 63122
United States
Pfizer Investigational Site
Saskatoon, Saskatchewan, S7L 2W1
Canada
Pfizer Investigational Site
ATHENS, , 15126
Greece
Pfizer Investigational Site
Montreal, Quebec, H1T 2M4
Canada
Pfizer Investigational Site
Tarrasa, CATALUNA, 08221
Spain
Pfizer Investigational Site
Hamilton, Ontario, L8V 1C3
Canada
Pfizer Investigational Site
San Antonio, Texas, 78229
United States
Pfizer Investigational Site
Winston Salem, North Carolina, 27103
United States
Pfizer Investigational Site
Saint-Nicolas, Quebec, G7A 2S2
Canada
Pfizer Investigational Site
Mineola, New York, 11501
United States
Pfizer Investigational Site
Cleveland, Ohio, 44106
United States
Pfizer Investigational Site
New York City, New York, 10003
United States
Pfizer Investigational Site
Sylmar, California, 91342
United States
Additional Information:
Study ID Numbers: A0661035;
Study Start Date:
Record last reviewed: November 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00035347
Other Pneumonia Studies:
1. Tigecycline for the Treatment of Subjects with Selected Serious Infections Due to Resistant Gram-Negative Organisms
2. Tigecycline versus Imipenem/Cilastatin for the Treatment of Subjects with Nosocomial Pneumonia
3. Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia.
4. Penicillin Prophylaxis in Sickle Cell Disease (PROPS)
5. Tigecycline versus Levofloxacin to Treat Subjects Hospitalized with Community-Acquired Pneumonia
Related Studies:
Other Pneumonia Clinical Trials
Other Alabama Clinical Trials
Other Phenix City Clinical Trials
Intravenous azithromycin plus intravenous ceftriaxone followed by oral azithromycin with intravenous levofloxacin followed by oral levofloxacin for the treatment of moderate to severely ill hospitalized patients with community acquired pneumonia.
|
|
|
|
|
|
|
|